What's Going On With Beam Therapeutics Stock?

Beam Therapeutics stock is surging to new heights today. What’s fueling BEAM momentum?Beam Surpasses Market ExpectationsBeam announced a loss per share of 10 cents, far surpassing the consensus estimate of a loss of 99 cents. Additionally, the company reported revenue of $114.11 million, dramatically exceeding expectations of $12.567 million.“In 2025, we established base editing as a best-in-class technology for genetic medicine, with positive proof-of-concept data and regulatory and clinical development pa ...